Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463842 | 1.00 | CA1 (0.59) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL5964968 | 0.88 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL5964943 | 0.88 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL347020 | 0.87 | PTGS2 (0.58) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL5312529 | 0.87 | PTGS2 (0.58) | CA1CA2CA9CA12PTGS2 | |
| Apricoxib SCHEMBL346028 | 0.86 | CA1 (0.60) | CA1CA2CA9CA12PTGS2 | |
| Apricoxib SCHEMBL3435344 | 0.86 | CA1 (0.60) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL2465664 | 0.85 | CHRNA7 (0.56) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL5314130 | 0.84 | CA9 (0.62) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL5309196 | 0.83 | CHRNA7 (0.66) | CA1CA2CA9CA12PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-20120052061-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | TRAGARA PHARMACEUTICALS INC. (US) | 2012-03-01 | — | — | US | claimed |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | TRAGARA PHARMACEUTICALS, INC (US) | 2011-12-15 | — | — | US | claimed |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | TRAGARA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | claimed |
| US-20110301209-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | claimed |
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | claimed |
| JP-2011506277-A | — | — | 2011-03-03 | — | — | JP | claimed |
| EP-2224932-A1 | CANCER TREATMENT USING COX-2 INHIBITOR AND ANTIMETABOLITE COMBINATIONS | Tragara Pharmaceuticals, Inc. (US) | 2010-09-08 | — | — | EP | claimed |
| EP-2205076-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR ÝERBB1¨AND HER-2 ÝERBB2¨ | Tragara Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009042612-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| WO-2009042613-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR [ERBB1] AND HER-2 [ERBB2] | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | claimed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | claimed |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | claimed |
| EP-1400243-A1 | Calcium-activated K channel activator | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-24 | — | — | EP | claimed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | claimed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | claimed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TP53, VHL, TSG101 | CA1 1526/4885CA2 2781/4885CA9 292/4885 |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TP53, VHL, TSG101 | CA1 1526/4885CA2 2781/4885CA9 292/4885 |
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | ERBB2, EGFR, ERBB3 | CA1 1238/4885CA2 188/4885CA9 573/4885 |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | CA1 981/4885CA2 520/4885CA9 665/4885 |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | PTGER2, PTGES2, PTGS2 | CA1 540/4885CA2 203/4885CA9 458/4885 |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | PTGS2, PTGES2, PTGER2 | CA1 914/4885CA2 141/4885CA9 572/4885 |
| US-20120052061-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | ERBB2, PTGER2, PTGS2 | CA1 963/4885CA2 75/4885CA9 407/4885 |
| US-20110301209-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TP53, VHL, TSG101 | CA1 1526/4885CA2 2781/4885CA9 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.